Cellular Mechanisms Regulating uPA in Hormone Refractory Prostate Cancer: A Novel Therapeutic Target
Abstract
DOD grant DAMDl7-00-1-0524 has the purpose of inhibiting the expression of two pathways critical to prostate cancer progression, one mediated by the tyrosine kinase receptor c- Met, and the second mediated by urokinase plasminogen activator (uPA) . Dr. Gary E. Gallick, Ph.D. became PI of the project upon after the departure from M.D. Anderson of Dr. Robert Radinsky. Because of the requirement for approval of change of PI and use of animals, work on this proposal commenced after January 1, 2001.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2001
- Accession Number
- ADA398158
Entities
People
- Gary E. Gallick
Organizations
- The University of Texas MD Anderson Cancer Center